The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Open accessAbstract
Purpose: The introduction of imatinib, a tyrosine kinase inhibitor (TKI), has greatly increased survival for patients with chronic myeloid leukemia (CML). Conversely, nonadherence to imatinib and other TKIs undoubtedly results in disease progression and treatment resistance. We examined trends in imatinib expenditures from 2002 to 2011 and assessed the association between copayment requirements for imatinib and TKI adherence. Patients and Methods: We used MarketScan health plan claims from 2002 to 2011 to identify adults (age 18 to 64 years) with CML who initiated imatinib therapy between January 1, 2002, and June 30, 2011, and had insurance coverage for at least 3 months before through 6 months after initiation (N = 1,541). Primary outcomes were TKI discontinuation and nonadherence. The primary independent variable was out-of-pocket cost for a 30-day supply of imatinib. By using a propensity-score weighted sample, we estimated the risk of discontinuation and nonadherence for patients with higher (top quartile) versus lower copayments. Results: Monthly copayments for imatinib averaged $108; median copayments were $30 (range, $0 to $4,792). Mean total monthly expenditures for imatinib nearly doubled between 2002 and 2011, from $2,798 to $4,892. Approximately 17% of patients with higher copayments and 10% with lower copayments discontinued TKIs during the first 180 days following initiation (adjusted risk ratio [aRR], 1.70; 95% CI, 1.30 to 2.22). Similarly, patients with higher copayments were 42% more likely to be nonadherent (aRR, 1.42; 95% CI, 1.19 to 1.69). Conclusion: Patients with higher copayments are more likely to discontinue or be nonadherent to TKIs. Given the importance of these therapies for patients with CML, our data suggest a critical need to reduce patient costs for these therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Marginal Structural Models and Causal Inference in Epidemiology
Robins, J. M., Hernán, M. Á., & Brumback, B. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00011 · Cited by 5,581
Development of a comorbidity index using physician claims data
Klabunde, C. N., Potosky, A. L., Legler, J. M., & Warren, J. L. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00256-0 · Cited by 1,845
Hernán, M. Á., Brumback, B., & Robins, J. M. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00012 · Cited by 1,782
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 1×
“To do this, we assumed an unobserved variable exists, such as lack of understanding of one’s illness, associated with both type of health plan and/or level of copayment and adherence.(29,30) We then re-estimated the association of copayment level with the outcomes after adjusting for this unmeasured variable under spe…”
BackgroundThe assessment of refill compliance using pharmacy records: Methods, validity, and applications
Steiner, J. F., & Prochazka, A. V. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00268-5 · Cited by 1,193
Marin, D., Bazeos, A., Mahon, F.-X., Eliasson, L., Milojkovic, D., Bua, M., Apperley, J. F., Szydlo, R., Desai, R., Kozlowski, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3087 · Cited by 909
Goldman, D. P., Joyce, G. F., & Zheng, Y. (2007) · JAMA · doi:10.1001/jama.298.1.61 · Cited by 874
Hess, L. M., Raebel, M. A., Conner, D. A., & Malone, D. C. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h018 · Cited by 756
Assessing the sensitivity of regression results to unmeasured confounders in observational studies
Lin, D. Y., Psaty, B. M., & Kronmal, R. A. (1998) · Biometrics · doi:10.2307/2533848 · Cited by 742
Schneeweiss, S. (2001) · American Journal of Epidemiology · doi:10.1093/aje/154.9.854 · Cited by 711
Gellad, W. F., Grenard, J. L., & Marcum, Z. A. (2011) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2011.02.004 · Cited by 692
Noens, L., van Lierde, M.-A., De Bock, R., Verhoef, G., Zachée, P., Berneman, Z., Martiat, P., Mineur, P., Van Eygen, K., MacDonald, K., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196543 · Cited by 616
Leukemia, E. I. C. M. (2013) · Blood · doi:10.1182/blood-2013-03-490003 · Cited by 592
Pharmacy Benefits and the Use of Drugs by the Chronically Ill
Goldman, D. P. (2004) · JAMA · doi:10.1001/jama.291.19.2344 · Cited by 530
Marginal Structural Models as a Tool for Standardization
Sato, T., & Matsuyama, Y. (2003) · Epidemiology · doi:10.1097/01.ede.0000081989.82616.7d · Cited by 455
VanderWeele, T. J., & Arah, O. A. (2011) · Epidemiology · doi:10.1097/ede.0b013e3181f74493 · Cited by 452
Gambacorti-Passerini, C., Antolini, L., Mahon, F.-X., Guilhot, F., Deininger, M., Fava, C., Nagler, A., Della Casa, C. M., Morra, E., Abruzzese, E., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr060 · Cited by 429
Neugut, A. I., Subar, M., Wilde, E. T., Stratton, S., Brouse, C. H., Hillyer, G. C., Grann, V. R., & Hershman, D. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3179 · Cited by 354
The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending
Huskamp, H. A., Deverka, P. A., Epstein, A. M., Epstein, R. S., McGuigan, K. A., & Frank, R. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmsa030954 · Cited by 334
Self-citationCenters for Medicare & Medicaid Services (CMS)
Services, U. S. C. F. M. M. (2013) · Cited by 318
Ibrahim, A. R., Eliasson, L., Apperley, J. F., Milojkovic, D., Bua, M., Szydlo, R., Mahon, F.-X., Kozlowski, K., Paliompeis, C., Foroni, L., et al. (2011) · Blood · doi:10.1182/blood-2010-10-309807 · Cited by 316
A comparison of comorbidity measurements to predict healthcare expenditures.
Farley, J. F., Harley, C., & Devine, J. W. (2006) · PubMed · Cited by 198
National Health Spending In 2004: Recent Slowdown Led By Prescription Drug Spending
Smith, C., Cowan, C., Heffler, S., & Catlin, A. (2006) · Health Affairs · doi:10.1377/hlthaff.25.1.186 · Cited by 163
Wu, E. Q., Johnson, S., Beaulieu, N., Arana, M., Bollu, V., Guo, A., Coombs, J., Feng, W., & Cortes, J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903396469 · Cited by 126
Huskamp, H. A., Deverka, P. A., Epstein, A. M., Epstein, R. S., McGuigan, K. A., Muriel, A. C., & Frank, R. G. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.435 · Cited by 72
Self-citationCost Sharing, Family Health Care Burden, and the Use of Specialty Drugs for Rheumatoid Arthritis
Karaca‐Mandic, P., Joyce, G., Goldman, D. P., & Laouri, M. (2010) · Health Services Research · doi:10.1111/j.1475-6773.2010.01117.x · Cited by 63
Incentive formularies and changes in prescription drug spending.
Landon, B. E., Rosenthal, M. B., Normand, S. T., et al. (2007) · PubMed · Cited by 33
Kim, Y. A., Rascati, K. L., Prasla, K., Godley, P. J., Goel, N., & Dunlop, D. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.021 · Cited by 29
Cited by
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547
“patients with CML [64, 65], TKI costs and cost effective-”
BackgroundKey, N. S., Khorana, A. A., Kuderer, N. M., Bohlke, K., Lee, A. Y. Y., Arcelus, J. I., Wong, S. L., Balaban, E. P., Flowers, C. R., Francis, C. W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01461 · Cited by 1,504
Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update
Oktay, K., Harvey, B. E., Partridge, A. H., Quinn, G. P., Reinecke, J., Taylor, H. S., Wallace, W. H., Wang, E. T., & Loren, A. W. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.1914 · Cited by 1,486
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Korde, L. A., Somerfield, M. R., Carey, L. A., Crews, J. R., Denduluri, N., Hwang, E. S., Khan, S. A., Loibl, S., Morris, E. A., Perez, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03399 · Cited by 1,040
Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
Ramsey, S. D., Bansal, A., Fedorenko, C. R., Blough, D. K., Overstreet, K. A., Shankaran, V., & Newcomb, P. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.6620 · Cited by 912
Metadata
- Authors
- Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-02-01
- Volume
- 32
- Issue
- 4
- Pages
- 306-311
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2140974115
- Cited by
- 500
- References
- 29
- FWCI
- 80.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.